An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Anna Spreafico, Dave Cescon, Marcus O Butler, Amit M Oza, Stephanie Lheureux, Neda Stjepanovic, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Pamela S Ohashi, Lillian L Siu, Daniel D De Carvalho
Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e000883; DOI: 10.1136/jitc-2020-000883